Company Prospect Business Plan

1. Page Company Presentation CSF Dynamics

2. Introduction Key persons behind CSFDynamics A/S Page MD, Dr.med.sci., University of Aarhus (1976), Specialist in Neurosurgery (1979). Currently employed as Chief Surgeon and Medical Director at PrivatHospitalet Danmark (1992-). Previously Dr. Børgesen was employed as chief neurosurgeon at the University Clinic of Neurosurgery at Rigshospitalet (1988-02), consultant at Arbejdsskadestyrelsen (1987-99), assistant neurologist at Sikringsstyrelsen (1986-87), consultant at the department of neurosurgery at KAS Glostrup (1984-87), consultant at the department of neurosurgery at Borgaspitalin in Iceland (1982-82). Dr. Børgesen is author and co-author of 86 scientific articles Svend Erik Børgesen Niels Agerlin MD from the University of Copenhagen (1986), Ph.D. from the University of Copenhagen (1993). Currently employed as Chief Neurosurgeon at the Neurosurgical dept. at KAS Glostrup (2002-). Previously employed as senior resident physician at the Neurosurgical dept. at KAS Glostrup (1997-01), resident physician and senior resident physician at the Neurosurgical dept. and Neurological dept. at Rigshospitalet (1988-96)

3. Introduction History of the SinuShunt Page Year Event 1993 The first animal experiment on dogs took place. 1994-95 Dr. Børgesen finished the first technical development of the SinuShunt and prepared the shunt ready for patenting. 26 Sep. 1996 An APCT application was filed for the USA, all of Europe, Japan, Hong Kong, Canada and Australia. 1997 The first SinuShunts were implanted. 1997-99 Clinical development and testing of the SinuShunt. 2000 The SinuShunt and the first results were presented at a neurosurgery world congress in Sydney. The interest was overwhelming. At that congress, the first contacts were made with university hospitals in Europe which wanted to participate in the future testing. The development started of a new shunt for treatment of hydrocephalus for infants and young children. At the same time the shunt for treatment of AD was developed. 2001 CSFDynamics entered into a production agreement with Medical Rubber AB in Sweden, a family-owned company established in 1973. The company, which is ISO 9002 and EN 46002 certified and has clean room facilities (class 10,000), currently produces the SinuShunt. 2002 The SinuShunt achieved the CE approval. Pilot testing and clinical studies continued in selected university hospitals in Europe. Jun. 2003 Dr. Børgesen received the Pudenz Award for 2002 for “Excellence in Cerebrospinal Fluid Physiology”. The award was given to Dr. Børgesen for “his many contributions over the years to the understanding of factors underlying the clinical physiology of hydrocephalus and his recent innovative studies utilizing the ventriculo-cranial venous sinus methodology for treatment of this condition”. End of 2003 Approx. 200 SinuShunts were implanted in selected hospitals 2007/2009 Development of a new and improved sinus-tube.

4. Introduction The SinuShunt Page

5. Introduction Illustration of the SinuShunt principle Page

6. Introduction The SinuShunt vs. traditional shunts Page SinuShunt Traditional shunts

7. Hydrocephalus Page

19. Hydrocephalus Technical details of the shunting principle Page Traditional shunts SinuShunt Traditional valves have large intervals for the intracranial pressure The SinuShunt does not have any interval for the intracranial pressure  ÷

24. Hydrocephalus Implanting the SinuShunt Page 1) Connector 2) Valves 3) Pre-chamber 4) Resistance tube 5) Drain for the transverse sinus Incision marks Position of the transverse sinus

28. Alzheimer’s Disease Page

37. Alzheimer’s Disease Physics of the MiniShunt Page Traditional shunts High pressure differential requires much higher resistance MiniShunt Low pressure differential enables much larger outflow with no overdrainage risk